The British-Swedish pharmaceutical company hopes the treatment will provide protection to the two per cent of the world’s population considered at increased risk of an inadequate response to a Covid vaccine.
AstraZeneca’s new Covid antibody shot for patients do not respond well to vaccines is said to be more than 80 per cent effective over six months.
The ground-breaking treatment, called AZD7442 or Evusheld, was found to reduce the risk of symptomatic Covid-19 by 83 per cent.
This includes people with blood cancers or other cancers being treated with chemotherapy, patients on dialysis, those taking medications after an organ transplant or immunosuppressive drugs for conditions including multiple sclerosis and rheumatoid arthritis.
The treatment is given as two sequential injections in the arm in one go.
AstraZeneca said there had been no cases of severe Covid or Covid-related deaths among those given the shot during the six-month Provent trial.
Hugh Montgomery, AZD7442 principal investigator, said protection was also maintained despite the surge of the Delta coronavirus variant.
Among those given a placebo injection, there were five severe cases of the disease and two deaths during the study.
A separate trial in patients with mild to moderate Covid-19 showed a higher dose of AZD7442 cut the risk of severe Covid or death by 88 per cent when treated within three days of first symptoms.
Mr Montgomery, professor of intensive care medicine at University College London, said: “These compelling results give me confidence that this long-acting antibody combination can provide my vulnerable patients with the long-lasting protection they urgently need to finally return to their everyday lives.
“Importantly, six months of protection was maintained despite the surge of the Delta variant among these high-risk participants who may not respond adequately to vaccination.”
AstraZeneca’s Provent trial involved 5,197 participants who were split into two groups at random, with one volunteer receiving a placebo injection of saline solution for every two people receiving a 300mg shot of AZD7442.
The trial took place at 87 sites across the US, UK, Spain, France and Belgium.
Volunteers will continue to be followed up for 15 months as part of the study.
